| Literature DB >> 29408905 |
Marianne A Bryan1, Daniela Giordano1,2, Kevin E Draves1,2, Richard Green1,2, Michael Gale1,2, Edward A Clark1,2.
Abstract
Although the spleen is a major site for West Nile virus (WNV) replication and spread, relatively little is known about which innate cells in the spleen replicate WNV, control viral dissemination, and/or prime innate and adaptive immune responses. Here we tested if splenic macrophages (MΦs) were necessary for control of WNV infection. We selectively depleted splenic MΦs, but not draining lymph node MΦs, by injecting mice intravenously with clodronate liposomes several days prior to infecting them with WNV. Mice missing splenic MΦs succumbed to WNV infection after an increased and accelerated spread of virus to the spleen and the brain. WNV-specific Ab and CTL responses were normal in splenic MΦ-depleted mice; however, numbers of NK cells and CD4 and CD8 T cells were significantly increased in the brains of infected mice. Splenic MΦ deficiency led to increased WNV in other splenic innate immune cells including CD11b- DCs, newly formed MΦs and monocytes. Unlike other splenic myeloid subsets, splenic MΦs express high levels of mRNAs encoding the complement protein C1q, the apoptotic cell clearance protein Mertk, the IL-18 cytokine and the FcγR1 receptor. Splenic MΦ-deficient mice may be highly susceptible to WNV infection in part to a deficiency in C1q, Mertk, IL-18 or Caspase 12 expression.Entities:
Mesh:
Year: 2018 PMID: 29408905 PMCID: PMC5800658 DOI: 10.1371/journal.pone.0191690
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 2Splenic MΦs are necessary for control of WNV infection.
(A) Experimental design; mice were treated with CLL or PBSL 3 days prior to subcutaneous (s.c.) footpad inoculation with WNV (1000 PFU) or vehicle control (CLL Mock). Mice depleted of splenic MΦs (triangles), unlike infected PBSL controls (squares) or CLL Mock mice (circles) all succumbed to WNV infection (MST = 11 days) (B); CLL treated mice had significantly decreased body weight at days 7–10 p.i (C) and had significantly increased disease scores at day 8–10 p.i. (D). (E) WNV RNA in sera (qPCR) of CLL-treated (white) vs. PBSL-treated control (black) mice at day 1 and day 2 post-WNV infection. (F) WNV RNA in popliteal (PO) and inguinal (IN) dLNs and in spleen of CLL treated (open) vs. PBSL control (black) mice at day 2 post-WNV infection. Viral levels determined by plaque assay in spleens (G) and brains (H) of CLL-treated (open) and PBSL-treated (black) mice days 2–8 pi. Statistics used were B: Log-Rank Test; C,D: Student’s t tests; and E-H: 1-way Anova plus Tukey’s post-test. P values: * p < 0.05, ** p <0.01, *** p<0.001, ND = not detected.